Endologix announced today that the first patients underwent a procedure using its Detour system since it received FDA approval. The FDA approved Detour for use in percutaneous transmural arterial bypass (PTAB) to treat peripheral arterial disease (PAD) last month. This initial procedure marks the official start of the company’s targeted market release of Detour in […]
Stents
2-year data supports Endologix Detour system for treating PAD
About a week after garnering FDA approval, Endologix announced positive 24-month data for its Detour system for treating PAD. Irvine, California–Endologix picked up premarket approval on June 7 for its Detour system to treat long, complex superficial femoropopliteal lesions. The DETOUR2 study evaluated the system’s performance in percutaneous transmural arterial bypass (PTAB). This approach aims […]
FDA approves new Endologix peripheral arterial disease treatment
Endologix recently announced it received FDA approval for its Detour system to treat long, complex superficial femoropopliteal lesions. Company officials describe the Detour system as a breakthrough in the treatment of peripheral arterial disease (PAD), which the CDC estimates affected roughly 6.5 million Americans over 40. The present recommended therapy is open surgical bypass, an […]
Gore initiates study to compare VBX stent graft, metal stenting
Gore announced today that it initiated a clinical study comparing its VBX stent graft to bare metal stenting. The FORWARD study evaluates the methods in the treatment of complex iliac occlusive disease. Gore’s prospective, multicenter, randomized controlled trial includes up to 40 sites in the U.S., Australia, New Zealand and Europe. The company estimates a […]
Inari Medical launches RevCore, Triever16 Curve catheters
Inari Medical today announced it launched two new catheters for venous stent thrombosis and venous thromboembolism. The Irvine, California-based company launched its RevCore thrombectomy catheter and the Triever16 Curve catheter. RevCore is a mechanical thrombectomy device for venous in-stent thrombosis, and Triever16 Curve is for pulmonary embolism and peripheral thrombectomy. “We are thrilled to announce […]
Conformal Medical raises $35M in oversubscribed Series D
Conformal Medical today announced the successful completion of its Series D funding round, where it raised a total of $35 million. The oversubscribed Series D was led by Sprig Equity, with participation from all major Series C investors. “Sprig Equity is focused on enabling transformative medical technology companies to achieve meaningful milestones and, more importantly, […]
Boston Scientific won’t buy majority stake in M.I. Tech
Boston Scientific (NYSE:BSX) will no longer be acquiring a majority stake in Korea-based medical device manufacturer M.I. Tech. The Marlborough, Massachusetts-based company announced plans to acquire a 64% stake in M.I. Tech in June 2022. It valued the deal at approximately $230 million. At the time, the company expected to close the transaction by the end […]
Abbott completes $890M acquisition of Cardiovascular Systems
Abbott announced today that it completed its acquisition of Cardiovascular Systems. In February, Abbott announced its agreement to acquire the atherectomy technology developer. Abbott agreed to pay $20 per common share of Cardiovascular Systems, leading to a total expected equity value of about $890 million. Cardiovascular Systems develops the Diamondback 360 system for atherectomy in […]
Olympus acquires GI stent maker Taewoong Medical for $370M
Olympus announced that it agreed to acquire Korea-based Taewoong Medical, a maker of medical devices, including stents, for $370 million. Taewoong Medical manufactures devices including gastrointestinal (GI) metallic stents. Olympus intends to use the acquisition to strengthen its GI endotherapy portfolio capabilities. According to a news release, Olympus plans to pay approximately $370 million in […]
Abbott to acquire Cardiovascular Systems for $890M
Abbott (NYSE: ABT) is making an important play to expand its cardiovascular device portfolio, announcing that it plans to acquire Cardiovascular Systems (Nasdaq: CSII). The two companies’ agreement, announced after market close yesterday, would provide $20 per common share for Cardiovascular Systems stockholders. The total expected equity value of the deal would be roughly $890 […]
Boston Scientific hit with $42M verdict in drug-eluting stents IP case
Boston Scientific (NYSE:BSX) must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled. The jury verdict yesterday came after the finding that Boston Scientific’s Synergy BP drug-eluting stents infringed on TissueGen and the university’s IP. The patent under question arose out of research that […]